Literature DB >> 12078904

Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues.

E Maggio1, A van den Berg, A Diepstra, J Kluiver, L Visser, S Poppema.   

Abstract

BACKGROUND: Hodgkin's lymphoma (HL) is characterized by a minority of neoplastic cells, the so-called Reed-Sternberg (RS) cells, and an admixture of reactive cells including lymphocytes, plasma cells, eosinophils and histiocytes. Cytokines produced in HL, either by RS or infiltrating cells, might explain the presence and maintenance of an impaired immune response. Chemokines (cytokines with chemoattractant properties) produced by RS cells play a major role in leukocyte trafficking. These molecules with specific receptor affinities contribute, for example by attracting TH2-like T cells, to the maintenance of a favorable environment for survival of RS cells. RESULTS AND DISCUSSION: Cross-talk between RS cells and reactive elements involves several cytokine/chemokines that process proliferative [interleukin (IL)-13 and IL-17], immunosuppressive (IL-10 and transforming growth factor-beta) and background formation (IL-5, TARC, MDC, IP-10, RANTES, Mig and others) messages. These autocrine and paracrine interactions lead to an environment where RS cells are able to proliferate, escape from apoptosis and survive host anti-tumor defense.
CONCLUSIONS: The proper modulation of these complex pathways may allow the development of new strategies in HL therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12078904     DOI: 10.1093/annonc/13.s1.52

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  34 in total

Review 1.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

2.  Myasthenia gravis remission and anti-AChR ab reduction after immunosuppressive and anti-neoplastic therapy in a patient with thymic Hodgkin's disease.

Authors:  M T Ferrò; T Riccardi; A Montanelli; P Bernasconi; R Mantegazza
Journal:  J Neurol       Date:  2006-09-29       Impact factor: 4.849

Review 3.  [Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets].

Authors:  C Renné; M L Hansmann; A Bräuninger
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

4.  Retrospective analysis of prognosticators in patients with relapsed Hodgkin's Lymphoma treated with autologous transplant: results of a single center.

Authors:  Aisha Masood; Amir Steinberg; Erin Moshier; Adriana Malone; Eileen Scigliano; Jacqueline Nieto; Keren Osman; Celia Grosskreutz; Luis Isola; Joshua Brody
Journal:  Med Oncol       Date:  2013-01-06       Impact factor: 3.064

5.  Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.

Authors:  Wouter J Plattel; Anke van den Berg; Lydia Visser; Anne-Marijn van der Graaf; Jan Pruim; Hans Vos; Bouke Hepkema; Arjan Diepstra; Gustaaf W van Imhoff
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

6.  Consecutive stimulation of HBsAg promotes the viability of the human B lymphoblastoid cell line IM-9 through regulating the SIRT1-NF-κB pathway.

Authors:  Jian Bo; Xiaojuan Wang; Jie Li; Wenqing Wang; Jinqian Zhang
Journal:  Oncol Lett       Date:  2017-05-03       Impact factor: 2.967

7.  Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies.

Authors:  Jianhua Zhou; Ning Kang; Lianxian Cui; Denian Ba; Wei He
Journal:  Cell Mol Immunol       Date:  2011-06-13       Impact factor: 11.530

Review 8.  Mechanisms underlying the association between obesity and Hodgkin lymphoma.

Authors:  Andreia Matos; Joana Marinho-Dias; Sofia Ramalheira; Maria José Oliveira; Manuel Bicho; Ricardo Ribeiro
Journal:  Tumour Biol       Date:  2016-07-27

9.  MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas.

Authors:  Kui Nie; Mario Gomez; Pablo Landgraf; Jose-Francisco Garcia; Yifang Liu; Leonard H C Tan; Amy Chadburn; Thomas Tuschl; Daniel M Knowles; Wayne Tam
Journal:  Am J Pathol       Date:  2008-07       Impact factor: 4.307

10.  CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.

Authors:  Takumi Kumai; Toshihiro Nagato; Hiroya Kobayashi; Yuki Komabayashi; Seigo Ueda; Kan Kishibe; Takayuki Ohkuri; Miki Takahara; Esteban Celis; Yasuaki Harabuchi
Journal:  Cancer Immunol Immunother       Date:  2015-03-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.